Paul Grint
Director/Board Member presso INHIBIKASE THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Paul C.
Grint currently works at Cardea Bio, Inc., as Chairman from 2020, Codagenix, Inc., as Chairman from 2022, Synedgen, Inc., as Director from 2014, CONNECT, as Director, Amplyx Pharmaceuticals, Inc., as Director from 2016, Inhibikase Therapeutics, Inc., as Independent Director from 2020, January Therapeutics, Inc., as Director from 2021, Persephone Biosciences, Inc., as Director, and CRISPRQC, Inc., as Director.
Dr. Grint also formerly worked at AmpliPhi Biosciences Corp., as Chief Executive Officer & Director from 2017 to 2019, Regulus Therapeutics, Inc., as President, Chief Executive Officer & Director from 2015 to 2017, Armata Pharmaceuticals, Inc., as Chief Executive Officer, Illumina, Inc., as Independent Director from 2011 to 2013, Pfizer Inc., as Chief Medical Officer, Schering-Plough Corp., as Chief Medical Officer, Kalypsys, Inc., as Chief Medical Officer in 2008, Cerexa, Inc., as President, IDEC Pharmaceuticals Corp., as Chief Medical Officer, Zephyr Sciences, Inc., as Chief Medical Officer & Senior Vice President, and Forest Research Institute, Inc., as Senior Vice President-Research from 2009 to 2011.
Dr. Grint received his doctorate degree from St Bartholomew's Hospital Medical College and undergraduate degree from St Mary's Hospital Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Paul Grint
| Società | Posizione | Inizio |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director/Board Member | 22/12/2020 |
CRISPRQC, Inc.
 CRISPRQC, Inc. BiotechnologyHealth Technology CRISPRQC, Inc. provides a comprehensive crispr analytics platform that enables scientists and researchers to optimize gene editing outcomes and ensure the highest levels of quality control. The company is based in San Diego, CA. The platform is built on the company's proprietary crispr-chip technology, which allows for direct, real-time measurement of crispr activity. The company strives to empower its customers with the insights needed to push forward the life-saving cures and sustainable agricultural advances fueled by crispr editing. CRISPRQC was founded by Ross Bundy and Kiana Aran, with Ross Bundy serving as the CEO since incorporation. | Director/Board Member | - |
January Therapeutics, Inc.
 January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | Director/Board Member | 05/05/2021 |
Persephone Biosciences, Inc.
 Persephone Biosciences, Inc. BiotechnologyHealth Technology Persephone Biosciences, Inc. engages in developing nutritional products to support the human gut microbiome. The company was founded by Stephanie Culler and is headquartered in Dan Diego, CA. | Director/Board Member | - |
Cardea Bio, Inc.
 Cardea Bio, Inc. BiotechnologyHealth Technology Cardea Bio, Inc. develops bioelectronics for use in research and diagnostics. Its products include AGILE 100 and pipeline. The company was founded by Ross Bundy, Kiana Aran, and Brett Goldsmith in 2013 and is headquartered in San Diego, CA. | Chairman | 01/04/2020 |
CONNECT
 CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Director/Board Member | - |
Synedgen, Inc.
 Synedgen, Inc. Pharmaceuticals: MajorHealth Technology Synedgen, Inc. operates as a biotechnology company leveraging a proprietary glycomics technology platform to develop modified therapeutic polysaccharides that target mucosal surfaces in genetic and acquired disorders. The firm’s products include Prisyna oral care and Synedgen wound care. The company was founded by William P. Wiesmann and Shenda Baker in 2009 and is headquartered in Claremont, CA. | Director/Board Member | 01/01/2014 |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Director/Board Member | 01/01/2016 |
Codagenix, Inc.
 Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | Chairman | 15/12/2022 |
Precedenti posizioni note di Paul Grint
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di Paul Grint
| St Bartholomew's Hospital Medical College | Doctorate Degree |
| St Mary's Hospital Medical School | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| ILLUMINA, INC. | Health Technology |
| REGULUS THERAPEUTICS INC. | Health Technology |
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| ARMATA PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 15 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
Synedgen, Inc.
Synedgen, Inc. Pharmaceuticals: MajorHealth Technology Synedgen, Inc. operates as a biotechnology company leveraging a proprietary glycomics technology platform to develop modified therapeutic polysaccharides that target mucosal surfaces in genetic and acquired disorders. The firm’s products include Prisyna oral care and Synedgen wound care. The company was founded by William P. Wiesmann and Shenda Baker in 2009 and is headquartered in Claremont, CA. | Health Technology |
Cardea Bio, Inc.
Cardea Bio, Inc. BiotechnologyHealth Technology Cardea Bio, Inc. develops bioelectronics for use in research and diagnostics. Its products include AGILE 100 and pipeline. The company was founded by Ross Bundy, Kiana Aran, and Brett Goldsmith in 2013 and is headquartered in San Diego, CA. | Health Technology |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Commercial Services |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Health Technology |
| Zephyr Sciences, Inc. | |
| Forest Research Institute, Inc. | |
Codagenix, Inc.
Codagenix, Inc. Medical/Nursing ServicesHealth Services Codagenix, Inc. provides platform technology to construct viral vaccines against multiple targets. It focuses on SAVE platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines for a range of medically important human diseases. The company was founded by J. Robert Coleman, Eckard Wimmer, Charlie Petty and Steffen Mueller in 2009 and is headquartered in Farmingdale, NY. | Health Services |
January Therapeutics, Inc.
January Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services January Therapeutics, Inc. provides biotechnology services. The company was founded by Robin Jackman and Neil Raheja and is headquartered in San Diego, CA. | Commercial Services |
Persephone Biosciences, Inc.
Persephone Biosciences, Inc. BiotechnologyHealth Technology Persephone Biosciences, Inc. engages in developing nutritional products to support the human gut microbiome. The company was founded by Stephanie Culler and is headquartered in Dan Diego, CA. | Health Technology |
CRISPRQC, Inc.
CRISPRQC, Inc. BiotechnologyHealth Technology CRISPRQC, Inc. provides a comprehensive crispr analytics platform that enables scientists and researchers to optimize gene editing outcomes and ensure the highest levels of quality control. The company is based in San Diego, CA. The platform is built on the company's proprietary crispr-chip technology, which allows for direct, real-time measurement of crispr activity. The company strives to empower its customers with the insights needed to push forward the life-saving cures and sustainable agricultural advances fueled by crispr editing. CRISPRQC was founded by Ross Bundy and Kiana Aran, with Ross Bundy serving as the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Paul Grint
